This study is an open-label, single-arm, dose-escalation and dose-expansion clinical trial designed to evaluate the maximum tolerated dose, safety, pharmacokinetic profile following administration of BR101 injection, and preliminary efficacy in subjects with relapsed or refractory multiple myeloma.
Voluntarily sign the informed consent form and be expected to complete follow-up examinations and treatments as required by the study procedures.
Aged 18 to 75 years (inclusive), with no gender restriction.
ECOG performance status of 0 or 1, and expected survival time ≥ 12 weeks.
Fibrinogen ≥ 1.0 g/L;
None
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lead sponsor
Byterna Therapeutics Ltd.
Collaborator